Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group Limited announced the cessation of 17,656 performance rights due to unmet conditions, effective May 5, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and strategic focus.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of oral and injectable products, catering to various therapeutic areas.
Average Trading Volume: 791,046
Technical Sentiment Signal: Hold
Current Market Cap: A$568.7M
Learn more about MYX stock on TipRanks’ Stock Analysis page.